Home›US Markets›M&A & Deals›Jefferies sets ₹1,600 target for Molbio Diagnostics af…

Jefferies sets ₹1,600 target for Molbio Diagnostics after IPO surge

Molbio Diagnostics priced its IPO at an upper band of ₹807 per share, debuted at ₹980 on Aug. 17, 2026, and later hit an NSE all-time high of ₹1,686.8.

Reported · Written up by our desk · M&A & Deals

LiveMint Markets reported that Jefferies has named Molbio Diagnostics as a top stock pick and set a target price of ₹1,600 for the newly listed shares.

The outlet said the IPO was available in the primary market last month at an upper price band of ₹807 per equity share, and the Goa-based company made its BSE and NSE debut on Aug. 17, 2026 at ₹980.

According to LiveMint Markets, Molbio Diagnostics delivered more than a 21% listing gain at debut, and the stock later extended gains to reach an all-time high of ₹1,686.8 on the NSE.

The outlet added that the share price later slipped from higher levels after profit-booking, after the strong early run.

More like this

Sources